Decrease of memory T helper cells (CD4+ CD45R0+) in hairy cell leukemia.

Abstract:

:Patients with hairy cell leukemia (HCL) are prone to opportunistic infections, which suggests an impaired T-cell functioning. To investigate a possible mechanism of such an impairment, we determined the numbers of naive and memory T cells by measuring the expression of CD45R0 on CD4+ and CD8+ T cells in 23 HCL patients. As control, 13 healthy subjects and 13 patients with other chronic B-cell leukemias were studied. In HCL patients with active disease, the percentage of CD4+ CD45R0+ T cells was significantly lower compared to healthy subjects (41% versus 57%, p = 0.01). Also the absolute numbers of CD4+ CD45R0+ T cells were reduced (396 x 10(6)/l versus 615 x 10(6)/l, p = 0.02) compared to healthy subjects, whereas within the CD8+ subset no differences were found. A contrasting elevation of percentages and numbers of CD45R0-expressing T cells (p < 0.0001) was seen in patients with chronic lymphocytic leukemia or leukemic non-Hodgkin's lymphoma. No relationship between CD4+ CD45R0+ and splenectomy, treatment with alpha-interferon or monocyte numbers was found in the HCL population. Despite the fact that the underlying mechanism of the reduced expression of CD45R0 in CD4+ T cells remains unclear, our observations may contribute to the understanding of an impaired T-cell functioning in HCL.

journal_name

Leukemia

journal_title

Leukemia

authors

van der Horst FA,van der Marel A,den Ottolander GJ,Kluin-Nelemans HC

subject

Has Abstract

pub_date

1993-01-01 00:00:00

pages

46-50

issue

1

eissn

0887-6924

issn

1476-5551

journal_volume

7

pub_type

杂志文章

相关文献

LEUKEMIA文献大全
  • In vivo thrombin and plasmin activities in patients with acute promyelocytic leukemia (APL): effect of all-trans retinoic acid (ATRA) therapy.

    abstract::APL-associated hemostasis disorders result from at least two distinct mechanisms due to the release of procoagulant activities and plasminogen activators from the leukemic cells. These two mechanisms (thrombin activation and plasmin activation) may cleave the fibrinogen molecule, but their respective roles in low fibr...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:

    authors: Dombret H,Scrobohaci ML,Daniel MT,Micléa JM,Castaigne S,Chomienne C,Fenaux P,Degos L

    更新日期:1995-01-01 00:00:00

  • Action of interferons in hairy cell leukemia.

    abstract::We have investigated the direct effects of interferon (IFN) on hairy cells (HCs) isolated from patients with hairy cell leukemia using one- and two-dimensional gel electrophoresis. We have previously characterized the induction of synthesis of 10-16 specific proteins by IFN-alpha 2b in HCs, as analyzed by one-dimensio...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:

    authors: Samuels BL,Rosner MC,Giometti CS,Golomb HM,Brownstein BH

    更新日期:1987-04-01 00:00:00

  • Survival time in a population-based consecutive series of adult acute myeloid leukemia--the prognostic impact of karyotype during the time period 1976-1993.

    abstract::A consecutive population-based series of 372 adult acute myeloid leukemias, successfully cytogenetically investigated at a single center between 1976 and 1993, is reported. All medical records were reviewed in order to ascertain the prognostic impact of karyotype, divided into three groups; favorable (t(8;21), t(15;17...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/sj.leu.2401788

    authors: Mauritzson N,Johansson B,Albin M,Rylander L,Billström R,Ahlgren T,Mikoczy Z,Strömberg U,Mitelman F,Hagmar L,Nilsson PG

    更新日期:2000-06-01 00:00:00

  • DNA profiling analysis of 100 consecutive de novo acute myeloid leukemia cases reveals patterns of genomic instability that affect all cytogenetic risk groups.

    abstract::We have carried out a high-resolution whole genome DNA profiling analysis on 100 bone marrow samples from a consecutive series of de novo acute myeloid leukemia (AML) cases. After discarding copy number changes that are known to be genetic polymorphisms, we found that genomic aberrations (GA) in the form of gains or l...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/sj.leu.2404653

    authors: Suela J,Alvarez S,Cifuentes F,Largo C,Ferreira BI,Blesa D,Ardanaz M,García R,Marquez JA,Odero MD,Calasanz MJ,Cigudosa JC

    更新日期:2007-06-01 00:00:00

  • Busulfan, cyclophosphamide and melphalan as conditioning regimen for bone marrow transplantation in children with myelodysplastic syndromes.

    abstract::As typical disorders of the elderly, myelodysplastic syndromes (MDSs) are relatively unusual in childhood. Nevertheless, up to 17% of cases of pediatric acute myeloid leukemia may have a preleukemic phase. In young patients, the goal of treatment is eradication of the preleukemic malignant clone and reconstitution of ...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:

    authors: Locatelli F,Pession A,Bonetti F,Maserati E,Prete L,Pedrazzoli P,Zecca M,Prete A,Paolucci P,Cazzola M

    更新日期:1994-05-01 00:00:00

  • High-affinity FRβ-specific CAR T cells eradicate AML and normal myeloid lineage without HSC toxicity.

    abstract::Acute myeloid leukemia (AML) is an aggressive malignancy, and development of new treatments to prolong remissions is warranted. Chimeric antigen receptor (CAR) T-cell therapies appear promising but on-target, off-tumor recognition of antigen in healthy tissues remains a concern. Here we isolated a high-affinity (HA) f...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/leu.2016.35

    authors: Lynn RC,Feng Y,Schutsky K,Poussin M,Kalota A,Dimitrov DS,Powell DJ Jr

    更新日期:2016-06-01 00:00:00

  • Does chemotherapy modify the immune surveillance of hematological malignancies?

    abstract::Malignant diseases induce immune responses against them which have variable success in controlling progression of disease. A variety of congenital and acquired disorders provide evidence in support of T cell or NK cell immune surveillance mechanisms in human hematological malignancies. Furthermore, clinical experience...

    journal_title:Leukemia

    pub_type: 杂志文章,评审

    doi:10.1038/leu.2008.273

    authors: Barrett AJ,Savani BN

    更新日期:2009-01-01 00:00:00

  • Phase II trial of recombinant human interferon alpha in myelodysplastic syndromes.

    abstract::Twenty patients with myelodysplastic syndromes were treated with daily subcutaneous injections of interferon alpha 2a, at the initial dose of 3 x 10(6) U/m2. Hemogram, chemistry profile, natural killer (NK) cell activity and lymphokine-activated killer (LAK) cell cytotoxicity were monitored serially. Bone marrow with ...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:

    authors: Nand S,Ellis T,Messmore H,Fisher SG,Gaynor E,Fisher RI

    更新日期:1992-03-01 00:00:00

  • γδT cells elicited by CMV reactivation after allo-SCT cross-recognize CMV and leukemia.

    abstract::Human cytomegalovirus (CMV) infections and relapse of disease remain major problems after allogeneic stem cell transplantation (allo-SCT), in particular in combination with CMV-negative donors or cordblood transplantations. Recent data suggest a paradoxical association between CMV reactivation after allo-SCT and reduc...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/leu.2012.374

    authors: Scheper W,van Dorp S,Kersting S,Pietersma F,Lindemans C,Hol S,Heijhuurs S,Sebestyen Z,Gründer C,Marcu-Malina V,Marchant A,Donner C,Plachter B,Vermijlen D,van Baarle D,Kuball J

    更新日期:2013-06-01 00:00:00

  • Cell-free transmission of Fv-4 resistance gene product controlling Friend leukemia virus-induced leukemogenesis in mice.

    abstract::Fv-4 is a mouse gene that dominantly confers resistance to infection by ecotropic murine leukemia virus (MuLV). The Fv-4' env antigen that binds to the cell surface of Fv-4'-bearing C3H cells was found in sera from normal Fv-4'-bearing C4W mice. The serum Fv-4' env antigen binds to ecotropic MuLV receptors, shown by s...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:

    authors: Kitagawa M,Aizawa S,Ikeda H,Hirokawa K

    更新日期:1997-04-01 00:00:00

  • Development of CAR-T cell therapies for multiple myeloma.

    abstract::Currently available data on chimeric antigen receptor (CAR)-T cell therapy has demonstrated efficacy and manageable toxicity in heavily pretreated multiple myeloma (MM) patients. The CAR-T field in MM is rapidly evolving with >50 currently ongoing clinical trials across all phases, different CAR-T design, or targets. ...

    journal_title:Leukemia

    pub_type: 杂志文章,评审

    doi:10.1038/s41375-020-0930-x

    authors: Gagelmann N,Riecken K,Wolschke C,Berger C,Ayuk FA,Fehse B,Kröger N

    更新日期:2020-09-01 00:00:00

  • Disruption of the MYC-miRNA-EZH2 loop to suppress aggressive B-cell lymphoma survival and clonogenicity.

    abstract::c-MYC (hereafter MYC) overexpression has been recognized in aggressive B-cell lymphomas and linked to adverse prognosis. MYC activation results in widespread repression of micro-RNA (miRNA) expression and associated with lymphoma aggressive progression. Our recent study identified a MYC-miRNA-EZH2 feed-forward loop li...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/leu.2013.94

    authors: Zhao X,Lwin T,Zhang X,Huang A,Wang J,Marquez VE,Chen-Kiang S,Dalton WS,Sotomayor E,Tao J

    更新日期:2013-12-01 00:00:00

  • In vitro responsiveness to interleukins and theophylline of CD16+, CD56- natural killer cells in a patient with chronic granular lymphocyte disorder.

    abstract::We report here the case of a 55-year-old patient with chronic granular lymphocyte disorder associated with moderate neutropenia. The majority of peripheral blood lymphocytes displayed a CD3-, CD8-, CD16+, CD56(NKH1)- phenotype. The patient's cells showed high spontaneous cytotoxic activity against K562 targets and dev...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:

    authors: Bayle C,Vitté-Mony I,Lang P,Pico J,Hercend T,Bertoglio J

    更新日期:1992-05-01 00:00:00

  • BET protein bromodomain inhibitor-based combinations are highly active against post-myeloproliferative neoplasm secondary AML cells.

    abstract::Myeloproliferative neoplasms with myelofibrosis (MPN-MF) demonstrate constitutive activation of Janus kinase/signal transducer and activator of transcription (JAK/STAT) signaling that responds to treatment with the JAK1 and 2 kinase inhibitor (JAKi) ruxolitinib. However, MPN-MF often progresses (~20%) to secondary acu...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/leu.2016.260

    authors: Saenz DT,Fiskus W,Manshouri T,Rajapakshe K,Krieger S,Sun B,Mill CP,DiNardo C,Pemmaraju N,Kadia T,Parmar S,Sharma S,Coarfa C,Qiu P,Verstovsek S,Bhalla KN

    更新日期:2017-03-01 00:00:00

  • Results of NOPHO ALL2008 treatment for patients aged 1-45 years with acute lymphoblastic leukemia.

    abstract::Adults with acute lymphoblastic leukemia (ALL) do worse than children. From 7/2008 to 12/2014, Nordic and Baltic centers treated 1509 consecutive patients aged 1-45 years with Philadelphia chromosome-negative ALL according to the NOPHO ALL2008 without cranial irradiation. Overall, 1022 patients were of age 1-9 years (...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/leu.2017.265

    authors: Toft N,Birgens H,Abrahamsson J,Griškevičius L,Hallböök H,Heyman M,Klausen TW,Jónsson ÓG,Palk K,Pruunsild K,Quist-Paulsen P,Vaitkeviciene G,Vettenranta K,Åsberg A,Frandsen TL,Marquart HV,Madsen HO,Norén-Nyström U,Schmi

    更新日期:2018-03-01 00:00:00

  • A 3-day schedule of fludarabine in previously treated chronic lymphocytic leukemia.

    abstract::This study was undertaken to determine the efficacy and toxicity of a shorter schedule of fludarabine administration (30 mg/m2 i.v. daily for 3 days every 4 weeks) in patients with previously treated chronic lymphocytic leukemia (CLL). Eighty patients with previously treated advanced (Rai III-IV) (54%) or progressive ...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:

    authors: Robertson LE,O'Brien S,Kantarjian H,Koller C,Beran M,Andreeff M,Lerner S,Plunkett W,Keating MJ

    更新日期:1995-09-01 00:00:00

  • The DNA methyltransferase inhibitors azacitidine, decitabine and zebularine exert differential effects on cancer gene expression in acute myeloid leukemia cells.

    abstract::The three DNA methyltransferase (DNMT)-inhibiting cytosine nucleoside analogues, azacitidine, decitabine and zebularine, which are currently studied as nonintensive therapy for myelodysplastic syndromes and acute myeloid leukemia (AML), differ in structure and metabolism, suggesting that they may have differential mol...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/leu.2008.397

    authors: Flotho C,Claus R,Batz C,Schneider M,Sandrock I,Ihde S,Plass C,Niemeyer CM,Lübbert M

    更新日期:2009-06-01 00:00:00

  • Different isoforms of the B-cell mutator activation-induced cytidine deaminase are aberrantly expressed in BCR-ABL1-positive acute lymphoblastic leukemia patients.

    abstract::The main reason for the unfavorable clinical outcome of BCR-ABL1-positive acute lymphoblastic leukemia (ALL) is genetic instability. However, how normal B-cell precursors acquire the genetic changes that lead to transformation has not yet been completely defined. We investigated the expression of the activation-induce...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/leu.2009.197

    authors: Iacobucci I,Lonetti A,Messa F,Ferrari A,Cilloni D,Soverini S,Paoloni F,Arruga F,Ottaviani E,Chiaretti S,Messina M,Vignetti M,Papayannidis C,Vitale A,Pane F,Piccaluga PP,Paolini S,Berton G,Baruzzi A,Saglio G,Baccar

    更新日期:2010-01-01 00:00:00

  • MRx102, a triptolide derivative, has potent antileukemic activity in vitro and in a murine model of AML.

    abstract::Triptolide, isolated from the herb Tripterygium wilfordii, has been shown to potently induce apoptosis in various malignant cells by inhibiting RNA synthesis and nuclear factor-κB activity. Previously, we showed that triptolide promotes apoptosis in acute myeloid leukemia (AML) cells via the mitochondria-mediated path...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/leu.2011.246

    authors: Carter BZ,Mak DH,Shi Y,Fidler JM,Chen R,Ling X,Plunkett W,Andreeff M

    更新日期:2012-03-01 00:00:00

  • hNUDC promotes the cell proliferation and differentiation in a leukemic cell line via activation of the thrombopoietin receptor (Mpl).

    abstract::We have recently identified a human homolog of a fungal nuclear migration protein (hNUDC) that binds specifically with the extracellular domain of thrombopoietin receptor (Mpl). Preliminary studies with human CD34(+) cells cultured in serum-free medium and normal mice showed that hNUDC appears to act as a cytokine, tr...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/leu.2008.20

    authors: Tang YS,Zhang YP,Xu P

    更新日期:2008-05-01 00:00:00

  • The biological consequences of excess GM-CSF levels in transgenic mice also lacking high-affinity receptors for GM-CSF.

    abstract::GM-CSF transgenic mice were crossed with mice with homozygous inactivation of the gene encoding the common beta chain (beta c) of the GM-CSF receptor to produce mice with constitutively elevated GM-CSF levels but no high-affinity GM-CSF receptors. GM-CSF transgenic beta c -/- mice had exceptionally elevated serum GM-C...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/sj.leu.2400926

    authors: Metcalf D,Mifsud S,Di Rago L,Robb L,Nicola NA,Alexander W

    更新日期:1998-03-01 00:00:00

  • Concordant bone marrow involvement of diffuse large B-cell lymphoma represents a distinct clinical and biological entity in the era of immunotherapy.

    abstract::In diffuse large B-cell lymphoma (DLBCL), the clinical and biological significance of concordant and discordant bone marrow (BM) involvement have not been well investigated. We evaluated 712 de novo DLBCL patients with front-line rituximab-containing treatment, including 263 patients with positive and 449 with negativ...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/leu.2017.222

    authors: Yao Z,Deng L,Xu-Monette ZY,Manyam GC,Jain P,Tzankov A,Visco C,Bhagat G,Wang J,Dybkaer K,Tam W,Hsi ED,van Krieken JH,Ponzoni M,Ferreri AJM,Møller MB,Winter JN,Piris MA,Fayad L,Liu Y,Song Y,Orlowski RZ,Kantarjia

    更新日期:2018-02-01 00:00:00

  • Clinical significance of CD81 expression by clonal plasma cells in high-risk smoldering and symptomatic multiple myeloma patients.

    abstract::The presence of CD19 in myelomatous plasma cells (MM-PCs) correlates with adverse prognosis in multiple myeloma (MM). Although CD19 expression is upregulated by CD81, this marker has been poorly investigated and its prognostic value in MM remains unknown. We have analyzed CD81 expression by multiparameter flow cytomet...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/leu.2012.42

    authors: Paiva B,Gutiérrez NC,Chen X,Vídriales MB,Montalbán MÁ,Rosiñol L,Oriol A,Martínez-López J,Mateos MV,López-Corral L,Díaz-Rodríguez E,Pérez JJ,Fernández-Redondo E,de Arriba F,Palomera L,Bengoechea E,Terol MJ,de Paz R,Mar

    更新日期:2012-08-01 00:00:00

  • Anti-leukemia activity of chaetocin via death receptor-dependent apoptosis and dual modulation of the histone methyl-transferase SUV39H1.

    abstract::Epigenetic deregulation is involved in acute myeloid leukemia (AML) pathogenesis and epigenetic targeting drugs are in clinical trial. Since the first results with histone-deacetylase inhibitors in AML are controversial, novel single and combined treatments need to be explored. It is tempting to combine chromatin-targ...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/leu.2011.271

    authors: Chaib H,Nebbioso A,Prebet T,Castellano R,Garbit S,Restouin A,Vey N,Altucci L,Collette Y

    更新日期:2012-04-01 00:00:00

  • Resistance to apoptotic cell death in a drug resistant T cell leukaemia cell line.

    abstract::In this study, we investigated the responses of the T cell leukaemia cell line, CCRF-CEM, and a vincristine-resistant subline, CEM/VCR R, to the induction of cell death by serum withdrawal. This treatment was used to overcome any contribution of P-glycoprotein-mediated drug resistance to the responses of the CEM/VCR R...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:

    authors: Geyp M,Ireland CM,Pittman SM

    更新日期:1996-03-01 00:00:00

  • Analysis of minimal residual disease by Ig/TCR gene rearrangements: guidelines for interpretation of real-time quantitative PCR data.

    abstract::Most modern treatment protocols for acute lymphoblastic leukaemia (ALL) include the analysis of minimal residual disease (MRD). To ensure comparable MRD results between different MRD-polymerase chain reaction (PCR) laboratories, standardization and quality control are essential. The European Study Group on MRD detecti...

    journal_title:Leukemia

    pub_type: 杂志文章,多中心研究

    doi:10.1038/sj.leu.2404586

    authors: van der Velden VH,Cazzaniga G,Schrauder A,Hancock J,Bader P,Panzer-Grumayer ER,Flohr T,Sutton R,Cave H,Madsen HO,Cayuela JM,Trka J,Eckert C,Foroni L,Zur Stadt U,Beldjord K,Raff T,van der Schoot CE,van Dongen JJ,Euro

    更新日期:2007-04-01 00:00:00

  • Diagnosis and monitoring in patients with hairy cell leukemia using the monoclonal antibody anti-HC2.

    abstract::Immunofluorescent staining of peripheral blood mononuclear cells with the monoclonal antibody anti-HC2 combined with phase microscopic examination identified leukemic hairy cells in nine of 13 patients (69%) evaluated at Memorial Hospital prior to treatment with recombinant alpha-interferon (rIFN-alpha A). The remaini...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:

    authors: Berman E,Posnett DN

    更新日期:1987-04-01 00:00:00

  • Identification of a gene element essential for leukemia-specific expression of transgenes.

    abstract::Leukemia-specific promoters and enhancers for gene therapy had never been reported. Since the Wilms' tumor gene WT1 is overexpressed in almost all types of leukemia, WT1 is an ideal target of leukemia-specific therapy. To explore the possibility of gene therapy for leukemia using WT1 promoter and enhancer, their activ...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/sj.leu.2403260

    authors: Hosen N,Yanagihara M,Nakazawa T,Kanato K,Nishida S,Shirakata T,Asada M,Masuda T,Taniguchi Y,Kawakami M,Tsuboi A,Ikegame K,Oka Y,Ogawa H,Kawase I,Oji Y,Sugiyama H

    更新日期:2004-03-01 00:00:00

  • A novel arsenical has antitumor activity toward As2O3-resistant and MRP1/ABCC1-overexpressing cell lines.

    abstract::Inorganic arsenic trioxide (As(2)O(3)) is a highly effective treatment for acute promyelocytic leukemia (APL). However, other cancers do not respond well to this form of arsenic at clinically achievable doses. We tested a novel arsenical, S-dimethylarsino-glutathione (darinaparsin) for efficacy in various malignancies...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/leu.2008.194

    authors: Diaz Z,Mann KK,Marcoux S,Kourelis M,Colombo M,Komarnitsky PB,Miller WH Jr

    更新日期:2008-10-01 00:00:00

  • Intraclonal diversification of immunoglobulin light chains in a subset of chronic lymphocytic leukemia alludes to antigen-driven clonal evolution.

    abstract::The study of intraclonal diversification (ID) in immunoglobulin (IG) genes offers valuable insight into the role of ongoing interactions with antigen in lymphomagenesis. We recently showed that ID in the IG heavy chain genes of patients with chronic lymphocytic leukemia (CLL) was generally limited; however, intense ID...

    journal_title:Leukemia

    pub_type: 杂志文章,多中心研究

    doi:10.1038/leu.2010.90

    authors: Kostareli E,Sutton LA,Hadzidimitriou A,Darzentas N,Kouvatsi A,Tsaftaris A,Anagnostopoulos A,Rosenquist R,Stamatopoulos K

    更新日期:2010-07-01 00:00:00